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Abstract Postmenopausal women with advanced breast
cancer recurring/progressing on or after initial (adjuvant or
first-line) endocrine therapy may be treated multiple times
with one of several endocrine or combinatorial targeted
treatment options before initiating chemotherapy. In the
absence of direct head-to-head comparisons of these treat-
ment options, an indirect comparison can inform treatment
choice. This network meta-analysis compared the efficacy of
everolimus plus exemestane with that of fulvestrant 250 and
500 mg in the advanced breast cancer setting following
adjuvant or first-line endocrine therapy. The reported hazard
ratios (HRs) for progression-free survival (PFS) or time to
progression from six studies that formed a network to
compare everolimus plus exemestane (BOLERO-2 trial)
with fulvestrant were analyzed by means of a Bayesian
network meta-analysis. In the primary comparison (PFS
analysis based on the local review of disease progression
from BOLERO-2 with the data from the other studies), ev-
erolimus plus exemestane appeared to be more efficacious
than both fulvestrant 250 mg (HR = 0.47; 95 % credible
interval [CrI] 0.38–0.58) and 500 mg (HR = 0.59; 95 % CrI
0.45–0.77). Similar results were obtained in an alternate
comparison based on central review of disease progression
from BOLERO-2 with the data from the other studies
(HR = 0.40; 95 % CrI 0.31–0.51 and HR = 0.50; 95 % CrI
0.37–0.67, respectively), and in a subgroup analysis of
patients who had received prior aromatase inhibitor therapy
(HR = 0.47; 95 % CrI 0.38–0.58 and HR = 0.55; 95 % CrI
0.40–0.76, respectively). These results suggest that everol-
imus plus exemestane may be more efficacious than fulve-
strant in patients with advanced breast cancer who progress
on or after adjuvant or first-line therapy with a nonsteroidal
aromatase inhibitor.
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Introduction
For patients with hormone-receptor-positive advanced
breast cancer, endocrine therapy is the recommended initial
treatment, and aromatase inhibitors (AIs) are the preferred
option for postmenopausal women because they elicit pro-
longed disease control compared with tamoxifen [1–3].
Treatment options for patients who experience disease pro-
gression after nonsteroidal AI therapy are limited. Recently,
the combination regimen of everolimus, an mTOR inhibitor,
and exemestane, a steroidal AI, was approved for use in this
setting based on significant improvement of progression-free
survival (PFS) versus exemestane alone [4]. Other options
include exemestane alone, fulvestrant (an estrogen-receptor
down-regulator), megestrol acetate, and chemotherapy
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[1–3]. Current guidelines recommend continued endocrine
therapy for responsive disease; however, clinical questions
regarding optimal sequencing of therapy remain [1–3].
Exemestane has shown activity in patients with
advanced breast cancer as a second- and third-line agent
following nonsteroidal AI treatment [5]. In patients who
had disease progression after first-line letrozole or anas-
trozole (n = 249), exemestane provided a clinical benefit
rate of 27 % with a median PFS of 3.4 months [5]. Even
after two prior endocrine treatments in the advanced breast
cancer setting (n = 60), exemestane demonstrated a clini-
cal benefit rate of 38 % [6].
Robust clinical evidence favoring the use of everolimus
plus exemestane rather than exemestane alone was demon-
strated in BOLERO-2, a phase 3 study in postmenopausal
women with hormone-receptor-positive, human epidermal
growth factor receptor 2 (HER2)-negative advanced breast
cancer progressing/recurring on/after nonsteroidal AI treat-
ment [4, 7]. In this study, median PFS was more than doubled
in the everolimus plus exemestane group (7.8 months vs 3.2
for exemestane alone, by local assessment; hazard ratio
[HR] = 0.45; P \ 0.0001). Central assessment of median
PFS confirmed the clinical benefit with everolimus plus ex-
emestane (11.0 months vs 4.1 for exemestane alone;
HR = 0.38; P \ 0.0001). In addition, PFS benefits were
consistent across patient subgroups defined by age, race,
presence of visceral metastases, and prior chemotherapy.
A clinical trial of fulvestrant 250 mg in postmenopausal
women with hormone-receptor-positive advanced breast
cancer progressing on nonsteroidal AI treatment showed a
similar duration of disease control as with exemestane
(median time to progression [TTP] = 3.7 months in both
treatment groups; HR = 0.963; P = 0.6531) [8]. However,
a clinical trial of fulvestrant 250 mg versus fulvestrant
500 mg in patients progressing after endocrine treatment
demonstrated a significant, albeit modest, improvement in
median PFS in the fulvestrant 500-mg group (5.5 vs
6.5 months, respectively; HR = 0.80; P = 0.006) [9]. In
patients previously treated with an AI, the magnitude of
median PFS benefit with 500 versus 250 mg fulvestrant was
less than in patients previously treated with an antiestrogen.
The currently available clinical evidence data support the
use of both everolimus plus exemestane and fulvestrant in
postmenopausal women with advanced breast cancer pro-
gressing on or after nonsteroidal AI therapy. However, the
limited clinical data on direct comparisons of these agents
present a challenge to optimization of disease management.
Although the apparent magnitude of PFS benefit with ever-
olimus plus exemestane exceeds that with fulvestrant, such
empirical cross-trial comparisons have limited validity. In
such cases, treatment decisions may be guided by an indirect
comparison, which can estimate relative efficacy parameters
of different treatment regimens across clinical studies.
For example, a recent indirect treatment comparison for the
efficacy of bevacizumab plus interferon-alpha-2a versus
tyrosine kinase inhibitors as first-line treatment in metastatic
renal cell carcinoma showed that the two treatment regimens
were similar with regard to PFS [10]. Guidelines for con-
ducting and interpreting indirect treatment comparisons
exist to standardize and support this area of research [11–13].
This network analysis was conducted to compare the efficacy
of everolimus plus exemestane versus fulvestrant in patients
with advanced breast cancer who are eligible for further
endocrine therapies.
Methods
Evidence base: search strategy
As everolimus (plus exemestane) and fulvestrant 250 mg
have both been compared with exemestane monotherapy, an
indirect comparison was possible through the common exe-
mestane arms in the studies. However, comparisons involving
fulvestrant 500 mg, and everolimus plus tamoxifen, required
the identification of additional studies with common treat-
ment/comparator arms to complete the network. Studies
connecting everolimus and fulvestrant were identified through
systematic reviews of treatments for advanced or metastatic
breast cancer found from a database search of the Cochrane
Library (CDSR, DARE, and HTA, 2010–2012), EMBASE,
and MEDLINE. Search terms included breast or mammary
and disease descriptors (cancer, neoplasm, oncology, tumor,
malignancy, carcinoma, adenocarcinoma, or sarcoma) as well
as metastasis, advanced, secondary, recurrent, inoperable,
disseminated, or incurable. Search terms for treatments
included everolimus or Afinitor as well as SDZ-RAD, rad001,
or 159351-69-6. Recent studies were identified through Web
site searches (National Horizon Scanning Centre, NICE,
FDA, EMA, ASCO, ESMO, ISPOR, ECCO, EBCC, and
SABCS) conducted March 8–9, 2012.
Eligible studies were assessed for quality based on seven
items: appropriate randomization; adequate concealment of
treatment allocation; groups similar at the onset of the
study in terms of prognostic factors, care providers, par-
ticipants, and outcome assessors blind to treatment allo-
cation; unexpected imbalances in dropouts between
groups; evidence to suggest that more outcomes were
measured than reported; intent-to-treat analysis; and
appropriate methods used to account for missing data.
Quality assessments and assumptions
Data extracted from each trial included design, methodol-
ogy, statistical methods, patient characteristics, and out-
come measures. Subgroup data, whenever possible, were
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analyzed for relevance. The primary analysis was for rel-
ative efficacy (PFS/TTP) between everolimus and fulve-
strant in the full patient population of the studies included
in the network, using the local assessment of PFS from
BOLERO-2. Secondary analyses included a subgroup
analysis by prior AI treatment and an additional analysis
for everolimus plus exemestane versus fulvestrant using the
BOLERO-2 central assessment of PFS. Using the con-
nector studies, exploratory analyses of the relative efficacy
of everolimus plus tamoxifen versus fulvestrant were
conducted. Additionally, the network meta-analysis of the
full patient population was performed for the relative
efficacy of everolimus plus tamoxifen versus fulvestrant
using the Howell study [14] in place of the Paridaens study
(which was a comparison of tamoxifen versus exemestane
and needed the SoFEA/EFECT studies to complete a net-
work for comparison versus fulvestrant 250 mg) as an
additional sensitivity analysis [15]. The Howell study was
identified following the systematic review, and therefore
did not have data extracted in as much detail as the other
studies and was not assessed for quality.
In conducting these analyses, several assumptions were
made regarding the data from the individual studies. For
the primary analysis, PFS and TTP were assumed to be
similar because disease-specific death events were included
in each endpoint in the studies analyzed. Moreover, as the
survival time in advanced breast cancer is shorter than in
early stage disease [9, 16], the majority of deaths were
assumed to be disease-specific.
Statistical analysis
All treatments evaluated in the primary analysis were
connected by one or more studies. Data consisted of the
HRs for PFS/TTP and the 95 % confidence intervals (CI)
for each of the trials as extracted from published reports.
The log HRs and their precision (reciprocal of the variance)
were calculated and input into the model. For the CON-
FIRM study, the HRs for the subgroup with prior AI
therapy were calculated from a digitized copy of the pub-
lished forest plot [9]. Accuracy was checked against cal-
culations for known results (all patients); resulting
differences on the HR scale were 0.005 or less. As not all
studies included outcome information on patients with
prior AI therapy, the only comparisons available were for
everolimus plus exemestane, exemestane alone, and ful-
vestrant 250 and 500 mg.
The indirect treatment comparison for relative efficacy
between everolimus (with exemestane or tamoxifen) and
fulvestrant used a Bayesian approach as described by Welton
et al. [17]. Specifically, a Bayesian fixed-effect model was
used to describe the log HRs. In this type of comparison,
evidence is synthesized from aggregate data arising from
randomized, controlled studies. Exemestane was adopted as
the reference treatment because it is used in clinical practice
and is the treatment with the most information in the net-
work; basic parameters of the model are the log HRs with
respect to exemestane. The log HR from each study was
assumed to be normally distributed, with the log HR mean
equaling the true log HR observed in each study and the
variance equaling the observed variability in each study. The
Markov chain Monte Carlo (MCMC) software WinBUGS
(version 1.4.3) was used to estimate the log HRs for each
possible pairwise comparison. For each outcome measure,
the analysis was performed with three chains, each run for a
series of 20,000 burn-in simulations to allow convergence.
Convergence was checked using the Gelman–Rubin statis-
tic, and a visual inspection demonstrated satisfactory con-
vergence by 20,000 iterations. A further 20,000 updates were
run for each chain, and estimates were obtained from those
updates. Median HRs and the 95 % credible interval (CrI)
are presented for the HRs. If the 95 % CrI does not include 1,
this suggests that there is evidence of a difference between
the treatments.
Results
Network analysis evidence base
A total of seven studies were identified that could be used
in a network analysis. Of these, only six were used to form
the basis of a network analysis, with the seventh [14] used
as an alternative for an additional sensitivity analysis. The
evidence network with the connections between the com-



























Fig. 1 Network of trials used to perform the analysis
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Fig. 1. Details of the individual study designs are provided
in Table 1 [4, 5, 7–9, 14, 15, 18]. All patients in the 7 trials
were postmenopausal and had locally advanced or meta-
static disease. All trials reported on PFS/TTP outcomes.
The TAMRAD study reviewed disease progression data
locally, whereas the BOLERO-2 study included both local
and central review. The other studies did not specifically
state that a central review was performed. In addition, all
but the open-label Paridaens and TAMRAD trials were
double-blind.
In general, the overall patient demographics and disease
characteristics were similar (Table 2) [4, 5, 8, 9, 14, 15,
18]. There were slight differences in the CONFIRM pop-
ulation versus the other primary studies regarding prior
treatments before study entry. Although all patients in
CONFIRM had prior endocrine therapy, prior AI therapy
was not an inclusion criterion, whereas the other primary
studies (except the Paridaens and Howell studies) had this
constraint. However, information from the subgroup of
patients who had prior AI treatment was available for
analysis from the CONFIRM study (as noted in the
statistical analysis), and was used in a comparison with the
other studies’ patient populations who had prior AI ther-
apy. The Paridaens and Howell studies also differed in
other prior treatment eligibility requirements. The Parida-
ens study permitted prior chemotherapy but not endocrine
therapy as first-line treatment in the advanced setting,
whereas in the Howell study, first-line treatment for met-
astatic disease was not allowed and information on patients
with prior AI therapy was not available. Hazard ratios for
PFS/TTP in each study used in the analyses are shown in
Table 3 [4, 5, 8, 9, 14, 15, 18, 19].
Analysis of efficacy
In the primary analysis, the results suggest that everolimus
plus exemestane is more efficacious for PFS/TTP than both
fulvestrant 250 (HR = 0.47; 95 % CrI 0.38–0.58) and
500 mg (HR = 0.59; 95 % CrI 0.45–0.77) (Table 4). The
exploratory analysis of the other pairwise comparisons (using
the Paridaens study) found no evidence of a difference
between everolimus plus tamoxifen and fulvestrant 250 or



















EVE ? EXE 62 (34–93) 44a 26 56 29 33 76
PBO ? EXE 61 (28–90) 40 26 56 33 30 77
CONFIRM [9]
FUL 500 mg 61 NR NR 66 NR NR NR
FUL 250 mg 61 NR NR 62 NR NR NR
EFECT [8]
FUL 63 (38–88) 42 25 56 35 31 67
EXE 63 (32–91) 49 22 58 36 32 66
Paridaens et al. [15]
EXE 63 (37–86) 24 4 48 NR NR 35
TAM 62 (37–87) 27 4 47 NR NR 35
SoFEA [5, 18]
FUL ? ANA 64 (57–72) NR NR 57 NR NR 15b
FUL 63 (57–74) NR NR 62 NR NR 16
EXE 66 (59–75) NR NR 58 NR NR 13
TAMRAD [19]
TAM 66 (42–86) 56 26 49 NR NR 79
TAM ? EVE 63 (41–81) 46 24 57 NR NR 76
Howell et al. [14]
FUL 67 (43–93) 23 NR NR 25 10 28
TAM 66 (43–92) 24 NR NR 25 10 33
ANA anastrozole, EVE everolimus, EXE exemestane, FUL fulvestrant, NR not reported, PBO placebo, TAM tamoxifen, yr year(s)
a Values for this study include neoadjuvant chemotherapy
b Values for this study represent the proportion of patients with bone-only metastases
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500 mg (Table 4). The analysis using the BOLERO-2 PFS
data based on central review suggested that everolimus plus
exemestane remained more efficacious for PFS/TTP than
fulvestrant 250 mg and fulvestrant 500 mg (HR = 0.40;
95 % CrI 0.31–0.51 and HR = 0.50; 95 % CrI 0.37–0.67,
respectively; Table 4).
The results of a sensitivity analysis based on an alternative
network, which substituted the Howell study for the Paridaens
study, were generally consistent with the analysis based on the
original network, although this exploratory analysis suggested
that everolimus plus tamoxifen is more efficacious for PFS/
TTP than fulvestrant 250 mg (HR = 0.46; 95 % CrI
0.29–0.71) and 500 mg (HR = 0.57; 95 % CrI 0.35–0.92).
Prior aromatase inhibitor therapy
In patients who received prior AI therapy, based on local
assessment of PFS from BOLERO-2, everolimus plus
exemestane was more efficacious for PFS/TTP than ful-
vestrant 250 and 500 mg (HR = 0.47; 95 % CrI 0.38–0.58
and HR = 0.55; 95 % CrI 0.40–0.76, respectively;
Table 5). Using the PFS data from the centrally reviewed
BOLERO-2 study did not substantially change the results
using the locally reviewed PFS data; everolimus plus
exemestane remained more efficacious for PFS/TTP than
fulvestrant 250 and 500 mg (Table 5).
Discussion
Direct comparative clinical evidence for optimal treatments
following a nonsteroidal AI in postmenopausal women with
hormone-receptor-positive advanced breast cancer is limited
[8, 20]. In this setting, clinical studies of endocrine mono-
therapy or combinations of endocrine agents have demon-
strated limited efficacy [8, 20], and the optimal sequence of
endocrine treatment remains unclear. In contrast, combining
endocrine agents with newer targeted agents (e.g., everoli-
mus) to block cell signaling pathways known to interact with
the estrogen receptor provided increased clinical benefits
versus endocrine monotherapy [4, 7]. In the absence of
head-to-head clinical studies, an indirect comparison of
clinical evidence can be used to provide estimates of relative
efficacy and inform treatment decisions.
In this network meta-analysis, everolimus plus exe-
mestane was shown to provide an improved PFS/TTP
compared with fulvestrant alone at either 250 or 500 mg.
Everolimus plus exemestane also provided greater clinical
benefit versus fulvestrant 250 and 500 mg in the subgroup
Table 3 Individual trial hazard ratios used in analysis
Trial Treatment Comparator Hazard
ratio
95 % CI
BOLERO-2 [4] EVE ? EXE EXE 0.45 0.38–0.54
Central review EVE ? EXE EXE 0.38 0.31–0.48
CONFIRM [9] FUL (500 mg) FUL (250 mg) 0.80 0.68–0.94
Prior AI
therapy
FUL (500 mg) FUL (250 mg) 0.85 0.67–1.08
EFECT [8] FUL (250 mg) EXE 0.96 0.82–1.13
Paridaens
et al. [15]
EXE TAM 0.87 0.70–1.08
SoFEA [5, 18] FUL (250 mg) EXE 0.95 0.79–1.14
TAMRAD [19] EVE ? TAM TAM 0.54 0.36–0.81
Howell et al. [14] FUL (250 mg) TAM 1.18 0.98–1.44
AI aromatase inhibitor, CI confidence interval, EVE everolimus, EXE ex-
emestane, FUL fulvestrant, TAM tamoxifen
Table 4 Efficacy of everolimus (EVE) plus exemestane (EXE) ver-
sus fulvestrant (FUL) and other pairwise comparisons in the total
patient population
Treatmentb Hazard ratio (95 % credible interval)a
Comparator
FUL 250 mg FUL 500 mg
Overall (local assessments)
EVE ? EXE 0.47 (0.38–0.58) 0.59 (0.45–0.77)
EVE ? TAM 0.65 (0.40–1.04) 0.81 (0.49–1.33)
Overall (BOLERO-2 central assessment)c
EVE ? EXE 0.40 (0.31–0.51) 0.50 (0.37–0.67)
TAM tamoxifen
a The hazard ratio (HR) is an estimate of the treatment hazard rate
divided by the comparator hazard rate; HR of [1 indicates that the
hazard rate is higher in the treatment group and the comparator group
is more effective; HR of\1 indicates that the hazard rate is higher in
the comparator group and the treatment group is more effective
b Primary analysis using the Paridaens study
c Central progression-free survival from BOLERO-2 was used
Table 5 Efficacy of everolimus (EVE) plus exemestane (EXE) ver-
sus fulvestrant (FUL) and other pairwise comparisons in patients with
prior aromatase inhibitor therapy
Treatment Hazard ratio (95 % credible interval)a
Comparator
FUL 250 mg FUL 500 mg
Prior aromatase inhibitor therapy (local assessment)
EVE ? EXE 0.47 (0.38–0.58) 0.55 (0.40–0.76)
Prior aromatase inhibitor therapy (central assessment from
BOLERO-2)
EVE ? EXE 0.40 (0.31–0.51) 0.47 (0.33–0.66)
a The hazard ratio (HR) is an estimate of the treatment hazard rate
divided by the comparator hazard rate; HR of [1 indicates that the
hazard rate is higher in the treatment group and the comparator group
is more effective; HR of\1 indicates that the hazard rate is higher in
the comparator group and the treatment group is more effective
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of patients who had prior AI therapy. The results from this
network analysis are supported, in part, by the clinical
evidence from an earlier network meta-analysis, which
reported that fulvestrant 500 mg was expected to be at least
as efficacious as exemestane alone in postmenopausal
women with advanced breast cancer who progressed on
endocrine therapy [21], and everolimus plus exemestane
was more efficacious than exemestane alone in this setting
[4]. Furthermore, in this earlier meta-analysis, fulvestrant
plus anastrozole did not increase clinical benefits (TTP and
overall survival) versus anastrozole alone in patients with
breast cancer at first relapse [22]. However, this patient
population was dissimilar (premenopausal patients were
included and very few patients received prior AI therapy)
to the patients in the current analysis.
The Decision Support Unit of National Institute for
Health and Clinical Excellence reports that network meta-
analyses may suffer from problems of unobserved effect
modifiers, as do pairwise meta-analyses [23]. However,
provided the constituent trials are unbiased and were con-
ducted in similar patient populations, both analyses should
result in unbiased estimates of treatment effects and are
superior to observational studies because they are based on
randomized comparisons [23]. However, there are limita-
tions inherent to these types of indirect comparisons. The
small number of included studies precluded a quantitative
exploration of heterogeneity among trial results. Hetero-
geneity is an important aspect in indirect analyses, and PFS
(used in this analysis to assess comparative efficacy) is
affected by patient prognosis at baseline. An important
feature of this methodology is that no assumptions are
made regarding trial-specific baselines and that between-
trial heterogeneity is set to zero, thus assuming homoge-
neity of the underlying true treatment effects. The CON-
FIRM trial did have a different patient population than the
other trials; however, the subgroup analysis of patients who
had prior AI therapy ameliorated those differences. The
patient populations from the Paridaens and Howell studies
were also different in terms of prior endocrine therapies,
which can bias the analysis, although they only affect the
exploratory comparison of everolimus plus tamoxifen
versus fulvestrant and do not affect the primary comparison
of everolimus plus exemestane versus fulvestrant. In
addition, the CONFIRM and EFECT studies did not have
data on HER2 status. Inclusion of a sizable proportion of
patients with HER2-positive disease may lower efficacy
results compared with the other studies that had a low
proportion of patients with HER2-positive disease.
Limitations specific to this network analysis include the
use of both double-blind and open-label trials and a com-
bination of two different outcome measures—PFS and
TTP. Although PFS and TTP can have dissimilar results
because deaths are not typically included in TTP, the two
outcome measures had overlapping criteria for disease-
specific deaths or deaths within 6 months of last tumor
assessment as an inclusion event in the network studies.
Survival time in advanced breast cancer is shorter than in
early stage disease [9, 16]; therefore, the majority of on-
study deaths were assumed to be disease-specific, and the
analysis assumed that PFS and TTP would yield similar
results.
In conclusion, this indirect treatment comparison suggests
that everolimus in combination with exemestane may be
more efficacious than fulvestrant 250 mg (HR = 0.47; 53 %
risk reduction of PFS event) and 500 mg (HR = 0.59; 41 %
risk reduction of PFS event) in postmenopausal women with
hormone-receptor-positive, advanced breast cancer that has
relapsed or progressed on/after a nonsteroidal AI. Future
trials should evaluate a selective combination of these
therapies to define an optimal treatment strategy.
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